Jefferies analyst Glen Santangelo raised the firm’s price target on HealthEquity (HQY) to $134 from $130 and keeps a Buy rating on the shares. The firm maintains its positive view on HealthEquity and points to the company’s solid Q2 and accompanying guidance raise as indications of continued strong execution by management that’s translating to stock-driving earnings outperformance. The meaningful tailwind from One Big Beautiful Bill Act’s expansion of HSA eligibility is a notable positive that should boost HealthEquity’s go-forward revenue and earnings outlooks, Jefferies adds. Concerns about interest rate outlook are more than adequately reflected in the stock, the firm argues.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HQY:
- HealthEquity’s Strong Financial Performance and Promising Outlook Justifies Buy Rating with $125 Price Target
- HealthEquity price target raised to $110 from $109 at RBC Capital
- HealthEquity price target raised to $126 from $125 at JPMorgan
- Healthequity’s Strong Financial Performance and Strategic Initiatives Drive Buy Rating
- Healthequity’s Strong Financial Performance and Strategic Initiatives Justify Buy Rating